American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (898)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (3939)
  2. Journal Article (1239)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (43)
  2. 2024 (217)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (4951)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5323)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor determinants of response to CAR-T therapy in relapsed or refractory mantle cell lymphoma
    Meeting Abstract

    Epstein-Peterson, Z. D.; Ryan, C. E.; Devlin, S. M.; Accav, N. G.; Avigdor, A.; Corona, M.; Danylesko, I.; Dela Cruz, J.; Goy, A.; Jacobson, C. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic determinants of resistance to anti-BCMA chimeric antigen receptor T-cell (CART) therapies in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Maura, F.; Freeman, C. L.; Lee, H.; Maclachlan, K. H.; Durante, M.; Ziccheddu, B.; Menges, M.; Diamond, B.; Papadimitriou, M.; Silva, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mutant RUNX1, SETBP1 and IDH mutant allele dynamics as biomarkers of hematologic response to IDH inhibitors in myeloid malignancies
    Meeting Abstract

    Chernak, B.; Song, A.; May, B.; Viny, A. D.
    Blood (2024)

    Fulltext@MSK | Save
  • Combined human and in vivo analyses implicate the critical importance of acute myeloid leukemia associated CD8 T cells and identifies their molecular dysfunction
    Meeting Abstract

    Chu, Y. E.; Cottam, M. A.; Potts, C. R.; Dickerson, K. M.; Jenkins, M. T.; Cartailler, J. A.; Lu, R.; Lee, S. C.; Levine, R. L.; Bowman, R. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A single-cell atlas of classical mantle cell lymphoma reveals paired tumor-immune malignant states correlating with prognosis
    Meeting Abstract

    Marouf, A.; Mitra, S.; Isgor, I.; Joseph, A.; Rahman, J.; Lin, Y. H.; Takizawa, M.; Chaligne, R.; Sethi, S.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis
    Meeting Abstract

    Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • TP53 alterations confer increased risk of leukemic transformation and worse survival as compared to high molecular risk mutations in patients with myeloproliferative neoplasms
    Meeting Abstract

    Handa, S.; Riazat-Kesh, Y. J. R. A.; Butterfield, R. J.; Sivakumar, G.; Venugopal, S.; McGovern, E.; Feld, J.; Tremblay, D.; Elghaity-Beckley, S.; Kremyanskaya, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Blachly, J. S.; Thirman, M. J.; Mannis, G. N.; Arellano, M. L.; DiPersio, J. F.; Traer, E.; Zwaan, C. M.; Shukla, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: Results of the phase 2 randomized PrECOG 0905 study in newly diagnosed FLT3 mutated AML
    Meeting Abstract

    Luger, S.; Chen, L.; Pratz, K. W.; Loghavi, S.; Perl, A. E.; Altman, J. K.; Redner, R. L.; Fathi, A. T.; Qasrawi, A.; Asch, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save